[1]
|
Pearson, G.J., Thanassoulis, G., Anderson, T.J., et al. (2021) 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 37, 1129-1150. https://doi.org/10.1016/j.cjca.2021.03.016
|
[2]
|
中国血脂管理指南修订联合专家委员会, 李建军, 赵水平, 等. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
|
[3]
|
Wheeler, D.C. (2009) The Jupiter Trial—New Territory for Statins? Nephrology Dialysis Transplantation, 24, 2036-2037.
https://doi.org/10.1093/ndt/gfp237
|
[4]
|
Cederberg, H., Stančáková, A., Yaluri, N., et al. (2015) Increased Risk of Diabetes with Statin Treatment Is Associated with Impaired Insulin Sensitivity and Insulin Secretion: A 6 Year Fol-low-Up Study of the METSIM Cohort. Diabetologia, 58, 1109-1117. https://doi.org/10.1007/s00125-015-3528-5
|
[5]
|
Kim, J., Lee, H.S. and Lee, K. (2018) Effect of Statins on Fasting Glucose in Non-Diabetic Individuals: Nationwide Population-Based Health Examination in Korea. Cardiovascular Dia-betology, 17, Article No. 155.
https://doi.org/10.1186/s12933-018-0799-4
|
[6]
|
Roy, R., Ajithan, A., Joseph, A., Mateti, U.V. and Subramanyam, K. (2019) Statin-Induced New Onset of Diabetes in Dyslipidemic Patients: A Retrospective Study. Postgraduate Medi-cine, 131, 383-387.
https://doi.org/10.1080/00325481.2019.1643636
|
[7]
|
Na, E., Cho, S., Kim, D.J., Choi, J. and Han, E. (2020) Time-Varying and Dose-Dependent Effect of Long-Term Statin Use on Risk of Type 2 Diabetes: A Retrospective Cohort Study. Cardiovascular Diabetology, 19, Article No. 67.
https://doi.org/10.1186/s12933-020-01037-0
|
[8]
|
Ridker, P.M., Pradhan, A., MacFadyen, J.G., Libby, P. and Glynn, R.J. (2012) Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: An Analysis from the JUPITER Trial. Center for Cardiovascular Disease Prevention, 380, 565-571. https://doi.org/10.1016/S0140-6736(12)61190-8
|
[9]
|
Crandall, J.P., Mather, K., Rajpathak, S.N., et al. (2017) Statin Use and Risk of Developing Diabetes: Results from the Diabetes Prevention Program. BMJ Open Diabetes Re-search & Care, 5, e438.
https://doi.org/10.1136/bmjdrc-2017-000438
|
[10]
|
Thakker, D., Nair, S., Pagada, A., Jamdade, V. and Malik, A. (2016) Statin Use and the Risk of Developing Diabetes: A Network Meta-Analysis. Pharmacoepidemiology and Drug Safety, 25, 1131-1149. https://doi.org/10.1002/pds.4020
|
[11]
|
Kamran, H., Kupferstein, E., Sharma, N., et al. (2018) Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis. Cardiorenal Medi-cine, 8, 105-112. https://doi.org/10.1159/000485196
|
[12]
|
Khan, S.U., Rahman, H., Okunrintemi, V., et al. (2019) Association of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 8, e011581. https://doi.org/10.1161/JAHA.118.011581
|
[13]
|
Sattar, N. (2023) Statins and Diabetes: What Are the Connections? Best Practice & Research Clinical Endocrinology & Metabolism, 37, Article ID: 101749. https://doi.org/10.1016/j.beem.2023.101749
|
[14]
|
Preiss, D., Seshasai, S.R.K., Welsh, P., et al. (2011) Risk of In-cident Diabetes with Intensive-Dose Compared with Moderate-Dose Statin Therapy: A Meta-Analysis. JAMA: Journal of the American Medical Association, 305, 2556-2564.
https://doi.org/10.1001/jama.2011.860
|
[15]
|
Hussain, A., Kaler, J. and Ray, S.D. (2023) The Benefits Outweigh the Risks of Treating Hypercholesterolemia: The Statin Dilemma. Cureus, 15, e33648. https://doi.org/10.7759/cureus.33648
|
[16]
|
Fiore, V., Barucca, A., Barraco, S., et al. (2023) Dyslipidemia and Car-diovascular Prevention in the Elderly: A Balance between Benefits and Risks of Statin Treatment in a Specific Population. Endocrine, Metabolic & Immune Disorders—Drug Targets, 23, 1371-1379. https://doi.org/10.2174/1871530323666230428092828
|
[17]
|
Laakso, M. and Fernandes Silva, L. (2023) Statins and Risk of Type 2 Diabetes: Mechanism and Clinical Implications. Frontiers in Endocrinology, 14, Article 1239335. https://doi.org/10.3389/fendo.2023.1239335
|
[18]
|
Ferri, N. and Corsini, A. (2020) Clinical Pharmacology of Statins: An Update. Current Atherosclerosis Reports, 22, Article No. 26. https://doi.org/10.1007/s11883-020-00844-w
|
[19]
|
Swerdlow, D.I., Preiss, D., Kuchenbaecker, K.B., et al. (2015) HMG-Coenzyme a Reductase Inhibition, Type 2 Diabetes, and Bodyweight: Evidence from Genetic Analysis and Ran-domised Trials. The Lancet, 385, 351-361.
https://doi.org/10.1016/S0140-6736(14)61183-1
|
[20]
|
Li, S. and Schooling, C.M. (2022) Investigating the Effects of Statins on Ischemic Heart Disease Allowing for Effects on Body Mass Index: A Mendelian Randomization Study. Scientific Reports, 12, Article No. 3478.
https://doi.org/10.1038/s41598-022-07344-8
|
[21]
|
Labos, C., Brophy, J.M., Smith, G.D., Sniderman, A.D. and Thanassoulis, G. (2018) Evaluation of the Pleiotropic Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Bi-ology, 38, 262-265.
https://doi.org/10.1161/ATVBAHA.117.310052
|
[22]
|
Gross, M., Schwartz, S.W., Sebastião, Y.V., Alman, A., Salemi, J.L., Ghimire-Aryal, P. and Foulis, P. (2023) LDL Reduction and Risk of Diabetes in Veteran Statin Users. An-nals of Pharmacotherapy, 57, 283-291.
https://doi.org/10.1177/10600280221115816
|
[23]
|
Yang, G.Y. and Schooling, C.M. (2023) Statins, Type 2 Diabe-tes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study. The Journal of Clinical Endocrinology & Metabolism, 108, 385-396.
https://doi.org/10.1210/clinem/dgac562
|
[24]
|
Reith, C., Baigent, C., Blackwell, L., et al. (2022) Effect of Statin Therapy on Muscle Symptoms: An Individual Participant Data Meta-Analysis of Large-Scale, Randomised, Dou-ble-Blind Trials. The Lancet, 400, 832-845.
|
[25]
|
Carmena, R. and Betteridge, D.J. (2019) Diabetogenic Action of Statins: Mechanisms. Current Atherosclerosis Reports, 21, Article No. 23. https://doi.org/10.1007/s11883-019-0780-z
|
[26]
|
Mehta, A., Dixon, D.L., Saeed, A., et al. (2023) With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs? Current Car-diology Reports, 25, 423-430.
https://doi.org/10.1007/s11886-023-01861-2
|
[27]
|
Banach, M. and Penson, P.E. (2020) Statins and LDL-C in Sec-ondary Prevention—So Much Progress, So Far to Go. JAMA Network Open, 3, e2025675. https://doi.org/10.1001/jamanetworkopen.2020.25675
|
[28]
|
Hoogwerf, B.J. (2023) Statins May Increase Diabetes, But Benefit Still Outweighs Risk. Cleveland Clinic Journal of Medicine, 90, 53-62. https://doi.org/10.3949/ccjm.90a.22069
|
[29]
|
Alvarez-Jimenez, L., Morales-Palomo, F., Moreno-Cabañas, A., et al. (2023) Effects of Statin Therapy on Glycemic Control and Insulin Resistance: A Systematic Review and Meta-Analysis. European Journal of Pharmacology, 947, Article ID: 175672. https://doi.org/10.1016/j.ejphar.2023.175672
|